Moleculin BiotechMBRX
13F holders, Q1 2026 (March 31)20holders +3
4new positions
3sold out
$2.29avg. 13F price*
At the end of Q1 2026, 20 institutions reported holding Moleculin Biotech Inc. (MBRX) in their 13F filings, up 3 from Q4 2025. 4 opened new positions and 3 sold out. The largest holders were Sabby Management, LLC ($172K), Geode Capital Management, LLC ($74K) and Vanguard Capital Management LLC ($32K).
- Company
- Moleculin Biotech Inc.
- CUSIP
- 60855D408
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $203K |
| Exits | 3 | $184K |
All 13F filers, Q4 2025 → Q1 2026: 110,615 shares bought and 58,129 shares sold, net +52,486 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 20 holders
| Sabby Management, LLC | 3.25% | New | 75,021 | $172K |
| Geode Capital Management, LLC | 0.00% | Add +113.6% | 32,329 | $74K |
| Vanguard Capital Management LLC | 0.00% | — | 13,869 | $32K |
| HRT Financial LP | 0.00% | New | 13,739 | $31K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 6,072 | $14K |
| Rockefeller Capital Management L.P. | 0.00% | Add +1928.0% | 4,421 | $10K |
| UBS Group AG | 0.00% | Reduce -41.9% | 3,409 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +31.7% | 1,835 | $4K |
| BlackRock, Inc. | 0.00% | Reduce -0.8% | 491 | $1K |
| EFG International AG | 0.00% | No change | 434 | $994 |
| Pinnacle Wealth Planning Services, Inc. | 0.00% | No change | 281 | $643 |
| NFSG Corp | 0.00% | No change | 114 | $261 |
| SBI Securities Co., Ltd. | 0.00% | Add +48.3% | 43 | $98 |
| Morgan Stanley | 0.00% | No change | 36 | $83 |
| Vanguard Global Advisers, LLC | 0.00% | — | 24 | $55 |
| FMR LLC | 0.00% | New | 3 | $7 |
| Danske Bank A/S | 0.00% | No change | 2 | $5 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 2 | $5 |
| Osaic Holdings, Inc. | 0.00% | No change | 1 | $2 |
| CVA Family Office, LLC | 0.00% | No change | 1 | $2 |
"% of holder's portfolio" is MBRX's weight in each manager's 13F, not the share of Moleculin Biotech Inc. the manager owns.